High Tumor Infiltrating Lymphocytes Are Significantly Associated with Increased Pathological Complete Response Rate in Patients with Triple Negative Breast Cancer and Treated with Neoadjuvant KEYNOTE 522 Chemoimmunotherapy
机构：[1]Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China河北医科大学第四医院[2]Univ Alabama Birmingham, Birmingham, AL USA[3]Emory Univ, Atlanta, GA USA[4]UAB Hosp, Birmingham, AL USA
Background: The current standard care for patients with triple
negative breast cancer (TNBC) is to administer the KEYNOTE-522
(KN522) regimen in the neoadjuvant setting. Little is known about
which biomarkers are associated with pathological complete
response (pCR) rate and outcome.
第一作者机构：[1]Fourth Hosp Hebei Med Univ, Shijiazhuang, Peoples R China
推荐引用方式(GB/T 7714)：
Deng Huiyan,Carames Gian,Gao Yuan,et al.High Tumor Infiltrating Lymphocytes Are Significantly Associated with Increased Pathological Complete Response Rate in Patients with Triple Negative Breast Cancer and Treated with Neoadjuvant KEYNOTE 522 Chemoimmunotherapy[J].LABORATORY INVESTIGATION.2025,105(3):doi:10.1016/j.labinv.2024.102359.
APA：
Deng, Huiyan,Carames, Gian,Gao, Yuan,Xu, Jiawen,Wu, Molly...&Li, Xiaoxian.(2025).High Tumor Infiltrating Lymphocytes Are Significantly Associated with Increased Pathological Complete Response Rate in Patients with Triple Negative Breast Cancer and Treated with Neoadjuvant KEYNOTE 522 Chemoimmunotherapy.LABORATORY INVESTIGATION,105,(3)
MLA：
Deng, Huiyan,et al."High Tumor Infiltrating Lymphocytes Are Significantly Associated with Increased Pathological Complete Response Rate in Patients with Triple Negative Breast Cancer and Treated with Neoadjuvant KEYNOTE 522 Chemoimmunotherapy".LABORATORY INVESTIGATION 105..3(2025)
